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Angiography and Interventional Cardiology
James P. Zidar, MD, FACC, FSCAI
Durham, North Carolina
The angiography and interventional cardiology working
group reviewed 1,095 abstracts for this year’s scientific
sessions and accepted 355. There were five areas of major
impact from the meeting: the use of distal projection
strategies for vein graft intervention and acute myocardial
infarction (AMI), new thromboatherectomy devices, the
role of inflammation in percutaneous coronary intervention
(PCI), new insights on drug-eluting stents, and peripheral
interventions.
DISTAL PROTECTION
In the setting of AMI, Drs. Gibson and Stone have
previously demonstrated that distal emboli and inflamma-
tion in the distal coronary bed predict 30-day and 1-year
mortality, even in the presence of Thrombolysis In Myo-
cardial Infarction grade 3 (TIMI-3) flow. Advancing this
work, Dr. Limbruno presented the Filter Wire Distal
Protection Trial in AMI. This 100-patient study enrolled
patients who presented with ST-segment elevation within
six hours and TIMI-3 flow in a native coronary vessel 3
mm. Patients were randomized to stent with or without the
protection of the distal filter wire. An improvement in
TIMI-3 flow and myocardial blush scores, more rapid
resolution of ST-segment changes, and improvement in
regional wall motion recovery and less distal emboli were
demonstrated in the treated group relative to the control
group. Dr. Stone presented the FIRE trial, comparing the
Filter Wire to the Percusurge Guard wire in saphenous vein
graft (SVG) intervention. This trial was designed as a
non-inferiority trial to the approved Guard Wire System.
Major adverse cardiac events (MACE) at 30 days with the
Filter Wire were equivalent to the Guard Wire, with respect
to death, myocardial infarction (MI), and urgent target
vessel revascularization.
Data were presented on the X-SIZER catheter, a throm-
boatherectomy device in AMI. Dr. Reimers and colleagues
randomized 92 patients with ST-segment elevation MI and
thrombus to the X-SIZER or control. Although there were
no differences in TIMI-3 flow, improvements in the more
sensitive score of myocardial blush were evident, along with
improvements in ST-segment elevation resolution and sig-
nificant reduction in angiographic complications. There are
also trends seen in the recovery of left ventricular function at
discharge and at 30 days. These two trials suggest that distal
protection offers a beneficial role to our SVG and AMI
angioplasty patients.
INFLAMMATION AND PCI
Turning to inflammation and its role in the angioplasty
laboratory, a group at the Cleveland Clinic randomized 75
patients who had elective angioplasty to pretreatment with
300 mg of clopidogrel versus no pretreatment. Dr. Frank
Zidar presented data on the inflammatory markers: C-reactive
protein, CD-40 ligand, P-selectin, and interleukin-6. Plate-From Duke University Medical Center, Durham, North Carolina.
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let expression was measured directly by flow cytometry.
Adenosine diphosphate-activated expression of P-selectin
and CD-40 ligand were reduced both pretreatment and
immediately post-angioplasty, with recovery back to normal
after the first 24 h. These reductions in inflammation may
explain part of the beneficial effect of clopidogrel pretreat-
ment in the larger PCI-CURE and CREDO trials.
Perhaps the most interesting trial was ISAR-REACT,
presented by Dr. Kastrati, randomizing 2,000 low-risk
patients undergoing elective angioplasty to adjunctive treat-
ment abciximab or placebo. Importantly, they pretreated
these patients for at least 2 h with a very large dose of Plavix
(600 mg/day), twice the standard U.S. loading dose. Im-
portantly, they excluded any high-risk or moderate-risk
patients, insulin-requiring diabetics, MI within two weeks,
unstable angina, any vein graft intervention, or ejection
fraction of 30%. With aggressive pretreatment, there was
no difference in death, MI, or the combination of death,
MI, or urgent revascularization at 30 days. Major and minor
bleeding rates were similar, but an increase in transfusions
was noted in the abciximab group. This study suggests that
a new antiplatelet strategy may be appropriate in the
low-risk, elective angioplasty patient.
DRUG-ELUTING STENTS (DES)
Dr. Bill O’Neill presented the primary end points of the
DELIVER trial, randomizing 1,043 U.S. patients to the
PENTA or the ACHIEVE stent (the PENTA stent with a
non–polymer-based paclitaxel coating). They randomized
1,043 patients. At nine months, there was no difference in
death or MI. There was a nonsignificant decrease in target
lesion revascularization with the rapid release of this drug-
eluting stent (10% reduced to 7%). The primary end point,
nine-month target vessel failure (defined as death, MI, or
revascularization of the target site) was reduced by 20% but
failed to achieve the prespecified 40% reduction. Angiogra-
phy was performed at baseline and eight months in three-
quarters of the patients. In this subgroup analysis, binary
restenosis was reduced from 22% to 16.7% with the
ACHIEVE stent (p  NS). The control group had lower
angiographic and clinical restenosis rates than anticipated,
whereas the drug-eluting stent group had higher rates than
predicted, resulting in a modest treatment effect. Clearly,
this system does reduce the incidence of fibrointimal hyper-
plasia within stent, but the magnitude of that effect is
modest and clearly not what has been demonstrated with
other drug-eluting stent trials.
One-year outcomes of the TAXUS II trial were pre-
sented by Dr. Antonio Columbo. This European trial tested
the polymer-based Boston Scientific paclitaxel NIR stent
with a control group and two treatment arms. Six-month
outcomes were presented at the TransCatheter Therapeu-
tics meeting 2002. Clopidogrel was prescribed for six
months post-PCI. An absolute reduction in major adverse
cardiac end points of 8.8% was evident at six months. At
12 months, this benefit increased to 10.5%. Therefore, it
appears that paclitaxel, on a polymer-based system with
prolonged delivery, appears efficacious and durable. The
U.S. interventional community awaits the results of the
U.S.-based TAXUS IV data later this year.
Dr. Leon presented a subanalysis of the SIRIUS trial, the
sirolimus-eluting BX Velocity stent compared with the
uncoated stent. The diabetic subgroup represented 28% of
the patients in the 1,000-patient trial. In this high-risk
group, sirolimus has much lower angiographic late-loss and
restenosis rates than the control group, resulting in signif-
icant reductions in target lesion revascularization and
MACE events at nine months. However, these results were
much less striking for the smaller subgroup of insulin-
requiring diabetics. More data are clearly warranted in this
challenging population.
Dr. Grube presented the first experience with the everoli-
mus coated S-stent, an analog of sirolimus. This small trial
(42 patients) compared the everolimus stent with the bare S
stent in a 2:1 randomization scheme. A unique feature of
this polymer-based system is the biodegradable delivery on
a metal stent. There was only one target lesion revascular-
ization in either group at six months. The angiographic and
intravascular ultrasound (IVUS) data were most interesting.
An 88% reduction in in-stent late loss (by angiography) and
a similar 87% reduction of in-stent plaque volume (by
IVUS) were noted in the DES versus control groups.
Dr. David Cohen presented an economic analysis of the
SIRIUS trial, an important issue for the interventional
community. An incremental increase of $2,000 was assessed
for the sirolimus stent versus the control stent. There was a
difference in in-hospital costs of approximately $2,800.
Most of the cost ($2,500) was recovered in one year as the
sirolimus-eluting stent had a reduction in clinical events. At
one year, the difference in costs is a modest $300, suggesting
a cost-effective strategy with a significant benefit for pa-
tients.
In the same American College of Cardiology session, the
FACIT trial was presented. The Swiss Heart study sug-
gested folate reduced restenosis by 50%. A group of Euro-
pean investigators led by Dr. Lange randomized 636 pa-
tients undergoing elective stenting to placebo or the
combination of folate, vitamin B12, and vitamin B6 in the
FACIT trial. At six months, the folate group had higher
restenosis and major cardiac event rates, questioning the
utility of folate in the angioplasty population.
Two presentations at the poster sessions addressed the
question of whether oral rapamycin would be an effective
alternative to minimize in-stent restenosis. Dr. Mehran’s
group gave the rapamycin drug, Rapamune, in two groups
of 15 stent patients, with stable or unstable angina and type
A or type B1 lesions. After a pretreatment dose of 6 mg,
group I received 2 mg/day for two weeks and group II
received 2 mg/day for four weeks. Apparently, this dose was
reasonably tolerated, except for several aphthous ulcers in
group II. Long-term data were only available for group I
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and revealed an angiographic late loss of 0.48 mm, half the
standard 0.8-mm late loss with conventional stents.
Clinical data on a new stent design, the Medtronic
DRIVER cobalt-chromium stent, were presented at this
meeting by Dr. Michael Sketch. This 300-patient registry
assessed outcomes with this thinner strut stent, using a
similar design to the S7 stent. Target lesion revasculariza-
tion at six months was 4%, and target vessel failure was
6.7%. In a 100-patient angiographic subgroup, the binary
restenosis rate was 15% and the late loss was 0.91 mm. This
new stent designs confer some benefit on angiographic
restenosis and clinical outcomes but still suffers from the
conventional late loss of 0.8 mm.
PERIPHERAL TRIALS
The ARCHeR trial was presented in the late breaking
clinical trials session by Dr. Mark Wholey. This prospective
registry assessed outcomes for carotid stenting in a high-risk
population for carotid endarterectomy. This multicenter
U.S. study required independent neurology assessment be-
fore enrollment. At baseline, asymptomatic patients had to
have 80% stenosis by angiography and symptomatic pa-
tients 50%. The Guidant ACCULINK stent (made of
self-expanding Nitinol available in tapered or non-tapered
designs) was used with distal protection (ACCUNET
filter). There were 513 patients enrolled in this registry over
two years, 476 registry patients, and 76 lead-in patients. Of
the high-risk entry criteria, a large percentage had restenosis
after carotid endarterectomy, low ejection fraction, heart
failure, 2-vessel coronary disease, the need for open heart
surgery within one month, or occlusion of the contralateral
carotid. Placement and delivery of the ACCUNET filter
was 93% successful. Debris was seen in 57% of the filters.
The composite event rate of death, MI, and stroke was
7.8%, including study-related and non–study-related events,
and 5.5% for study-related events. The findings are concur-
rent with the SAPHIRE data presented at the 2002
American Heart Association annual meeting by Dr. Yadav.
The PARIS trial, presented by Dr. Ron Waxman, ran-
domized 200 patients with SFA disease to primary angio-
plasty versus angioplasty with brachytherapy using a gamma
source, iridium 192. Percutaneous transluminal angioplasty
of the SFA is an area fraught with high restenosis rates. They
attempted to randomize 300 patients but were only able to
enroll 200 patients before the sponsor stopped the study after
three years. Repeat angiograms were available for 135 patients.
Contrary to most radiation trials, there was no benefit for
brachytherapy in this trial. This trial demonstrates the chal-
lenges of randomized trials in the peripheral circulation.
SUMMARY
New devices have continued to test conventional interven-
tional approaches to common clinical challenges. Adjunctive
pharmacologic strategies are evolving (i.e., the clopidogrel
dose). Worldwide experience with drug-eluting stents is ex-
panding rapidly. The first drug-eluting stent should be avail-
able in the U.S. within the month. Two carotid stent trials
have shown favorable data in high-risk patient subsets. These
landmark studies should lead to approval and use in the general
clinical community within the year.
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Summary of Special Topics Presentations
William S. Weintraub, MD, FACC
Atlanta, Georgia
Mallemala et al. (1) studied the effect of loss of social
support on quality-of-life benefits after coronary revascular-
ization in an observational study of 271 percutaneous
coronary intervention (PCI) patients and 224 coronary
artery bypass graft (CABG) patients. The primary outcome
measure was the Seattle Angina Questionnaire, and social
support was measured with the Enriched Social Support
Inventory. There was less quality-of-life improvement at six
months for both CABG and PCI in patients who suffered
loss of social support. This study is one of the first to show
that social support is actually critical to recovery after
revascularization.
Bakhai et al. (2) studied the impact of diabetes on clinical
and economic outcomes of PCI in the elderly, using an
administrative database. There was a trend toward higher
mortality (12.1% vs. 8.6%, p  0.081), more clinical
restenosis (11.9% vs. 8.4%, p  0.001), and more repeat
procedures in the diabetic patients (PCI 9.2% vs. 7.0%, p 
0.004, CABG 3.3% vs. 2.0%, p  0.012). Costs at one year
were also higher in the diabetic patients, whether there was
restenosis ($26,158 vs. $22,178, p  0.001) or no restenosis
($4,937 vs. $2,299, p  0.001). Also, the cost of restenosis
was higher in diabetic patients. Cardiovascular care for
diabetics remains a serious problem; this study documents
not only poor outcome in older diabetics, but higher costs as
well.From the Department of Medicine, Emory University, Atlanta, Georgia.
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